A practical reference on dose range: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-07 and is reviewed periodically as new material appears.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Acceptance sampling procedures became common during World War II. Sampling plans, such as MIL-STD-105, were developed by Harold F. Dodge and others and became frequently used as standards. More recently, quality assurance broadened the scope beyond final inspection to include all aspects of manufacturing. Broader quality management systems include methodologies such as statistical process control, HACCP, six sigma, and ISO 9000. Some use of acceptance sampling still remains.
Aldo-keto reductase family 1 (AKR1) is a family of aldo-keto reductase enzymes that is involved in steroid metabolism. It includes the AKR1C and AKR1D subgroups, which respectively consist of AKR1C1–AKR1C4 and AKR1D1. Together with short-chain dehydrogenase/reductases (SDRs), these enzymes catalyze oxidoreductions, act on the C3, C5, C11, C17 and C20 positions of steroids, and function as 3α-HSDTooltip 3α-Hydroxysteroid dehydrogenases, 3β-HSDsTooltip 3β-Hydroxysteroid dehydrogenases, 5β-reductases, 11β-HSDsTooltip 11β-Hydroxysteroid dehydrogenases, 17β-HSDsTooltip 17β-hydroxysteroid dehydrogenases, and 20α-HSDsTooltip 20α-Hydroxysteroid dehydrogenases, respectively. The AKR1C enzymes act as 3-, 17- and 20-ketosteroid reductases, while AKR1D1 acts as the sole 5β-reductase in humans. AKR1A1; AKR1B1; AKR1B10; AKR1C1; AKR1C2; AKR1C3; AKR1C4; AKR1D1; Others Steroidogenic enzyme
The reticulocyte production index (RPI), also called a corrected reticulocyte count (CRC), is a calculated value used in the diagnosis of anemia. This calculation is necessary because the raw reticulocyte count is misleading in anemic patients. The problem arises because the reticulocyte count is not really a count but rather a percentage: it reports the number of reticulocytes as a percentage of the number of red blood cells. In anemia, the patient's red blood cells are depleted, creating an erroneously elevated reticulocyte count.
The 1-deoxysphingolipids (1-deoxySLs) are a recently identified class of atypical sphingolipids (SLs). They are produced via a non-canonical biosynthetic pathway, and their defining feature, the absence of a C1 hydroxyl group (C1-OH), prevents their further conversion into complex sphingolipids. Under normal conditions, sphingolipids are synthesized through a reaction catalyzed by the enzyme serine-palmitoyltransferase (SPT), which condenses serine with palmitoyl-CoA. However, when SPT utilizes alternative amino acid substrates such as alanine or glycine instead of serine, it leads to the formation of 1-deoxySLs. Unlike canonical sphingolipids, 1-deoxysphingolipids cannot be degraded via standard catabolic pathways. As a result, they accumulate to high levels and have been implicated in a range of neurological and metabolic disorders. There are two types of 1-deoxySLs: 1-deoxysphinganine and 1-deoxymethylsphinganine.
39. Pain Physician. 2026 Sep;29(6):E753-E754. In Response to Comment on "Cervical Erector Spinae Plane Block vs. Epidural Steroid Injection for Cervical Radicular Pain: A Clinical Trial". Salehi S(1)(2). Author information: (1)Iran University of Medical Sciences, Tehran, Iran. (2)Department of Anesthesiology and Pain Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Sources: en.wikipedia.org
On sale from 3 July 2007. The list was compiled through a combination of suggestions from Edge readers, Edge staff and additional "industry experts". Each game in the list had a retrospective article, a full-page illustration, and a sidebar listing readers' comments. In addition, the volume contained reprints of the magazine's previous "Top 100" lists from 2000 (issue 80) and 2003 (issue 128). The top 10 of Edge Presents The 100 Best Videogames were: The Legend of Zelda: Ocarina of Time Resident Evil 4 Super Mario 64 Half-Life 2 Super Mario World The Legend of Zelda: A Link to the Past Halo: Combat Evolved Final Fantasy XII Tetris Super Metroid An Edge Special Edition - "the 100 greatest videogames" (2015)
=== Social control and conformity === The concept of "mental illness" is often used to label and control those with beliefs and behaviours that the majority of people disagree with. The basic premise of the anti-psychiatry movement is that psychiatrists attempt to classify "normal" people as "deviant", psychiatric treatments are ultimately more damaging than helpful to patients; psychiatry's history involves discredited treatments, such as psychosurgery, an example of this being the frontal lobectomy (commonly called a lobotomy). The use of lobotomies largely disappeared by the late 1970s. On Michel Foucault's Madness and Civilization, Sapouna (2001) writes, "[his book provides] a framework to conceptualize confinement as a process of exclusion and 'silencing of the mad'."
(2026) study the anatomy of ulna and femur or Sahelanthropus tchadensis, interpreted as indicative of presence of adaptations to bipedalism in spite of similarities in size and geometric morphometric shape to bones of chimpanzees. De Jager et al. (2026) study the frequency, position, and variability of cortical sulcal imprints in endocasts of extant chimpanzees and bonobos, providing a comparative resource for the studies of the brain evolution based on hominin fossils. Dunbar (2026) reevaluates data from the study of Deaner & Nunn (1999), finds evidence of changes in brain size following increases in body size in the evolution of primates but in a more complicated way that suggested by the original brain lag hypothesis, with an increase in body size followed by a progressively greater increase in brain size, and finds evidence of such evolution of brain and body size in hominins.
== Function == In the heart, specialized cardiac muscle cells transmit electrical impulses from the atrioventricular node (AV node) to the Purkinje fibers – fascicles, also referred to as bundle branches. These start as a single fascicle of fibers at the AV node called the bundle of His that then splits into three bundle branches: the right fascicular branch, left anterior fascicular branch, and left posterior fascicular branch.
=== Traditional inhibitors === Traditionally, there were two major corrosion inhibitors used in vehicles: silicates and phosphates. American-made vehicles traditionally used both silicates and phosphates. European makes contain silicates and other inhibitors, but no phosphates. Japanese makes traditionally use phosphates and other inhibitors, but no silicates.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.